Table 1.

Toxicities, outcomes, and patient response with BRAF and MEK inhibitors after immunotherapy

Pt. No.	BRAF status	Prior therapies	Duration between last anti PD-1 therapy and initiation of BRAF-MEK inhibitor (days)	Reaction	Immune mechanism as underlying cause	Duration between reaction and initiation of BRAF-MEK inhibitor	Response	Progression-free survival (days)	Overall survival (days)
1	V600E	Pembrolizumab, pembrolizumab+CMP001	21	G3 rash	Possible	12	PR	85	140
2	V600E	pembrolizumab+SD-101	27	G3 rash	Possible	9	PR	195*	NA
3	V600E	Pembrolizumab+IDO inhibitor	13	Grade 2 nausea and vomiting	Unlikely	49	PR	136*	NA
4	V600E	Pembrolizumab+IDO inhibitor	85	Grade 2 fever	Unlikely	22	PR	111	131
5	V600E	Ipilimumab and nivolumab	31	Grade 3 pneumonitis	Possible	1	PR	68	81
6	V600E	Pembrolizumab+IDO inhibitor	56	Grade 3 liver enzyme elevation	Unlikely	41	SD	238	398
7	V600R	Pembrolizumab with IDO inhibitor, pembrolizumab with CMP-001	12	Grade 2 nausea, poor appetite, and chills	Possible	42	PR	408	NA
8	V600E	Ipilimumab, pembrolizumab, pembrolizumab + CMP-001	27	Grade 3 cytokine release syndrome	Probable	15	PR	181+	NA
9	V600E	pembrolizumab + IDO inhibitor, ipilimumab +IDO inhibitor	28	Grade 3 cytokine release syndrome	Probable	17	PR	422+	NA
10	V600K	Pembrolizumab, pembrolizumab+CMP001	54	Grade 3 rash	Possible	22	SD	104#	110#
11	V600E	Ipilimumab, pembrolizumab	25	Grade 3 rash	Possible	14	NA	UNK	335

^*- On treatment and continue to be progression-free

^#- Duration in days since starting vemurafenib

⁺- Continue to be progression-free without any treatment